Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 2, 2014, Pages 529-538

  Chittasupho, Chuda ^a   Lirdprapamongkol, Kriengsak ^b   Kewsuwan, Prartana ^c   Sarisuta, Narong ^d  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b Krung Thep Maha Nakhon   (Thailand)

^c Thailand Institute of Nuclear Technology   (Thailand)

^d THAMMASAT UNIVERSITY   (Thailand)

Author keywords

A549 cells; CXCR4; CXCR4 antagonist; Doxorubicin; Lung cancer; Targeted drug delivery

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DOXORUBICIN; POLYGLACTIN; ANTINEOPLASTIC ANTIBIOTIC; CXCR4 PROTEIN, HUMAN; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

A549 CELL LINE; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; LUNG CANCER; NANOENCAPSULATION; PARTICLE SIZE; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; LACTIC ACID; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; POLYGLYCOLIC ACID; RECEPTORS, CXCR4;

EID: 84908373348     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.06.020     Document Type: Article

References (42)

1. M.Z. Dewan, S. Ahmed, Y. Iwasaki, K. Ohba, M. Toi, and N. Yamamoto Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer Biomed. Pharmacother. 60 6 2006 273 276
2. C.H. Tang, T.W. Tan, W.M. Fu, and R.S. Yang Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis Carcinogenesis 29 1 2008 35 43
3. R.J. Phillips, M.D. Burdick, M. Lutz, J.A. Belperio, M.P. Keane, and R.M. Strieter The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases Am. J. Respir. Crit. Care Med. 167 12 2003 1676 1686
4. M. Arya, H. Ahmed, N. Silhi, M. Williamson, and H.R. Patel Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration Tumour Biol. 28 3 2007 123 131
5. P.M. Murphy Chemokines and the molecular basis of cancer metastasis N. Engl. J. Med. 345 11 2001 833 835
6. T. Mori, R. Doi, M. Koizumi, E. Toyoda, D. Ito, K. Kami, T. Masui, K. Fujimoto, H. Tamamura, K. Hiramatsu, N. Fujii, and M. Imamura CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer Mol. Cancer Ther. 3 1 2004 29 37
7. T. Engl, B. Relja, D. Marian, C. Blumenberg, I. Muller, W.D. Beecken, J. Jones, E.M. Ringel, J. Bereiter-Hahn, D. Jonas, and R.A. Blaheta CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins Neoplasia 8 4 2006 290 301
8. T. Kakinuma, and S.T. Hwang Chemokines, chemokine receptors, and cancer metastasis J. Leukoc. Biol. 79 4 2006 639 651
9. A. Zlotnik, A.M. Burkhardt, and B. Homey Homeostatic chemokine receptors and organ-specific metastasis Nat. Rev. Immunol. 11 9 2011 597 606
10. M. Darash-Yahana, E. Pikarsky, R. Abramovitch, E. Zeira, B. Pal, R. Karplus, K. Beider, S. Avniel, S. Kasem, E. Galun, and A. Peled Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis FASEB J. 18 11 2004 1240 1242
11. T. Gangadhar, S. Nandi, and R. Salgia The role of chemokine receptor CXCR4 in lung cancer Cancer Biol. Ther. 9 6 2010 409 416
12. D. Mukherjee, and J. Zhao The role of chemokine receptor CXCR4 in breast cancer metastasis Am. J. Cancer Res. 3 1 2013 46 57
13. S. Singh, U.P. Singh, W.E. Grizzle, and J.W. Lillard Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion Lab. Invest. 84 12 2004 1666 1676
14. Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U.K. Singha, C.M. Pitsillides, J.A. Spencer, T. Kimlinger, J.M. Ghobrial, X. Jia, G. Lu, M. Timm, A. Kumar, D. Cote, I. Veilleux, K.E. Hedin, G.D. Roodman, T.E. Witzig, A.L. Kung, T. Hideshima, K.C. Anderson, C.P. Lin, and I.M. Ghobrial Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma Blood 109 7 2007 2708 2717
15. A.C. Spoo, M. Lubbert, W.G. Wierda, and J.A. Burger CXCR4 is a prognostic marker in acute myelogenous leukemia Blood 109 2 2007 786 791
16. T. Murakami, A.R. Cardones, and S.T. Hwang Chemokine receptors and melanoma metastasis J. Dermatol. Sci. 36 2 2004 71 78
17. F. Marchesi, P. Monti, B.E. Leone, A. Zerbi, A. Vecchi, L. Piemonti, A. Mantovani, and P. Allavena Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4 Cancer Res. 64 22 2004 8420 8427
18. J.A. Burger, and A. Peled CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers Leukemia 23 1 2009 43 52
19. H. Tsutsumi, T. Tanaka, N. Ohashi, H. Masuno, H. Tamamura, K. Hiramatsu, T. Araki, S. Ueda, S. Oishi, and N. Fujii Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents Biopolymers 88 2 2007 279 289
20. H. Tamamura, Y. Xu, T. Hattori, X. Zhang, R. Arakaki, K. Kanbara, A. Omagari, A. Otaka, T. Ibuka, N. Yamamoto, H. Nakashima, and N. Fujii A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140 Biochem. Biophys. Res. Commun. 253 3 1998 877 882
21. Z. Liang, T. Wu, H. Lou, X. Yu, R.S. Taichman, S.K. Lau, S. Nie, J. Umbreit, and H. Shim Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4 Cancer Res. 64 12 2004 4302 4308
22. H. Tamamura, A. Hori, N. Kanzaki, K. Hiramatsu, M. Mizumoto, H. Nakashima, N. Yamamoto, A. Otaka, and N. Fujii T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer FEBS Lett. 550 1-3 2003 79 83
23. E. De Clercq Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100 Mini Rev. Med. Chem. 5 9 2005 805 824
24. S. Hong, P.R. Leroueil, I.J. Majoros, B.G. Orr, J.R. Baker Jr., and M.M. Banaszak Holl The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform Chem. Biol. 14 1 2007 107 115
25. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. USA 103 16 2006 6315 6320
26. R.N. Johnson, P. Kopeckova, and J. Kopecek Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20 Bioconjug. Chem. 20 1 2009 129 137
27. H. Meng, J.Y. Chen, L. Mi, P.N. Wang, M.Y. Ge, Y. Yue, and N. Dai Conjugates of folic acids with BSA-coated quantum dots for cancer cell targeting and imaging by single-photon and two-photon excitation J. Biol. Inorg. Chem. 2010
28. H.D. Han, L.S. Mangala, J.W. Lee, M.M. Shahzad, H.S. Kim, D. Shen, E.J. Nam, E.M. Mora, R.L. Stone, C. Lu, S.J. Lee, J.W. Roh, A.M. Nick, G. Lopez-Berestein, and A.K. Sood Targeted gene silencing using RGD-labeled chitosan nanoparticles Clin. Cancer Res. 16 15 2010 3910 3922
29. R.A. Petros, and J.M. DeSimone Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discov. 9 8 2010 615 627
30. K. Avgoustakis Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery Curr. Drug Deliv. 1 4 2004 321 333
31. R.K. Subedi, K.W. Kang, and H.K. Choi Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin Eur. J. Pharm. Sci. 37 3-4 2009 508 513
32. J. Cheng, B.A. Teply, I. Sherifi, J. Sung, G. Luther, F.X. Gu, E. Levy-Nissenbaum, A.F. Radovic-Moreno, R. Langer, and O.C. Farokhzad Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery Biomaterials 28 5 2007 869 876
33. J. Davda, and V. Labhasetwar Characterization of nanoparticle uptake by endothelial cells Int. J. Pharm. 233 1-2 2002 51 59
34. M. Huang, C.W. Fong, E. Khor, and L.Y. Lim Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation J. Control. Release 106 3 2005 391 406
35. D. Fahham, I.D. Weiss, M. Abraham, K. Beider, W. Hanna, Z. Shlomai, O. Eizenberg, G. Zamir, U. Izhar, O.M. Shapira, A. Peled, and O. Wald In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer J. Thorac. Cardiovasc. Surg. 144 5 2012 1167 1175 e1
36. J.A. Burger, D.J. Stewart, O. Wald, and A. Peled Potential of CXCR4 antagonists for the treatment of metastatic lung cancer Expert Rev. Anticancer Ther. 11 4 2011 621 630
37. O. Wald, O.M. Shapira, and U. Izhar CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential Theranostics 3 1 2013 26 33
38. S. Otsuka, and G. Bebb The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer J. Thorac. Oncol. 3 12 2008 1379 1383
39. C. Guo, and R.A. Gemeinhart Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles Eur. J. Pharm. Biopharm. 70 2 2008 597 604
40. F. Tewes, E. Munnier, B. Antoon, L. NgaboniOkassa, S. Cohen-Jonathan, H. Marchais, L. Douziech-Eyrolles, M. Souce, P. Dubois, and I. Chourpa Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods Eur. J. Pharm. Biopharm. 66 3 2007 488 492
41. R.J. Phillips, J. Mestas, M. Gharaee-Kermani, M.D. Burdick, A. Sica, J.A. Belperio, M.P. Keane, and R.M. Strieter Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha J. Biol. Chem. 280 23 2005 22473 22481
42. C. Murdoch, P.N. Monk, A. Finn, Functional expression of chemokine receptor CXCR4 on human epithelial cells, Immunology 98 (1) (1999) 3641.